Volato Announces Receipt of Continued Listing Standards Notice From NYSE AmericanThe Associated PressATLANTA ATLANTA–(BUSINESS WIRE)–Mar 20, 2026– Volato Group, Inc. (the “Company” or “Volato”) (NYSE ...

The proposed business combination was initially announced on July 8, 2025. NEW YORK, March 20, 2026 (GLOBE NEWSWIRE) -- ReserveOne, Inc. ("ReserveOne") and ReserveOne Holdings, In ...

Global Ship Lease, Inc. (NYSE:GSL) (the 'Company'), a containership owner and lessor, filed its Annual Report on Form 20-F for the year ended December 31, 2025 (the 'Form 20-F') with the U.S.

The University of Florida increased spending 27% in men’s basketball after Todd Golden’s 2nd season, ahead of the 2025 national title run.

Biofrontera Inc. beats earnings expectations. Reported EPS is $0.5, expectations were $0.195. Operator: Welcome to the ...

Operator: Good afternoon, ladies and gentlemen, and welcome to the Sera Prognostics, Inc. Fourth Quarter 2025 Financial Results Conference Call. At this time, all lines are in a listen-only mode.

FedEx Corp. (NYSE: FDX) today reported the following consolidated results for the third quarter ended February 28 (adjusted measures exclude the items listed below): ...

DHT Holdings, Inc. (NYSE:DHT) (the “Company”) has filed its 2025 annual report on Form 20-F with the U.S. Securities and Exchange Commission (the “SEC”).

Good morning, and welcome to Biofrontera Inc.'s fourth quarter and full year 2025 financial results and business update conference call. Please note that certain information discussed during today's ...

POTOMAC, MD / ACCESS Newswire / March 19, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, ...

Good day, and welcome to the One Stop Systems, Inc. Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded. As part of the discussion today, ...

I am excited and honored to join Longeveron at this pivotal moment for the company. The strength of the company's stem cell science and success in multiple clinical trials across several indications ...